245 related articles for article (PubMed ID: 15899725)
21. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
[TBL] [Abstract][Full Text] [Related]
22. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
Rostaing L; Christiaans MH; Kovarik JM; Pascual J
Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487
[TBL] [Abstract][Full Text] [Related]
23. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851
[TBL] [Abstract][Full Text] [Related]
25. Considerations in sirolimus use in the early and late post-transplant periods.
Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
[TBL] [Abstract][Full Text] [Related]
26. Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Vanrenterghem Y
Ther Drug Monit; 2003 Aug; 25(4):447-51. PubMed ID: 12883227
[TBL] [Abstract][Full Text] [Related]
27. A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection.
Fukudo M; Yano I; Katsura T; Ito N; Yamamoto S; Kamoto T; Ogawa O; Inui K
Drug Metab Pharmacokinet; 2010; 25(5):411-7. PubMed ID: 20834189
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
Ettenger RB; Grimm EM
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
[TBL] [Abstract][Full Text] [Related]
30. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.
Nielsen FT; Ottosen P; Starklint H; Dieperink H
Nephrol Dial Transplant; 2003 Mar; 18(3):491-6. PubMed ID: 12584269
[TBL] [Abstract][Full Text] [Related]
31. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
32. Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics.
Braun F; Schöcklmann H; Ziegler E; Kunzendorf U; Armstrong VW; Renders L
Clin Pharmacol Ther; 2009 Oct; 86(4):411-5. PubMed ID: 19606088
[TBL] [Abstract][Full Text] [Related]
33. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.
Monchaud C; Marquet P
Clin Pharmacokinet; 2009; 48(7):419-62. PubMed ID: 19691367
[TBL] [Abstract][Full Text] [Related]
35. Sirolimus: a new option in transplantation.
Mota A
Expert Opin Pharmacother; 2005 Mar; 6(3):479-87. PubMed ID: 15794738
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.
Chueh SC; Wang SM; Lai MK; Chen J
Transplant Proc; 2004 Sep; 36(7):2058-9. PubMed ID: 15518745
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety.
Velosa JA; Larson TS; Gloor JM; Stegall MD
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S3-S10. PubMed ID: 11583938
[TBL] [Abstract][Full Text] [Related]
38. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients.
Uchida K; Hoshinaga K; Watarai Y; Goto N; Kusaka M; Sasaki H; Hirano M;
Transplant Proc; 2014 Jun; 46(5):1314-8. PubMed ID: 24935294
[TBL] [Abstract][Full Text] [Related]
40. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
